Vermilion Energy had 3 analyst reports since August 11, 2015 according to SRatingsIntel. The stock has an average rating of "Hold" and a consensus target price of $60.79. They set an "in-line" rating and a $73.00 price objective on the stock. The stock of FCB Financial Holdings, Inc. The firm has "Hold" rating by Desjardins Securities given on Tuesday, August 11. The firm has "Buy" rating given on Friday, February 26 by Stifel Nicolaus. The rating was maintained by Piper Jaffray on Monday, November 16 with "Neutral". Invesco Ltd reported 411,024 shares. The rating was downgraded by WallachBeth Capital on Tuesday, November 17 to "Hold". See Thermo Fisher Scientific Inc. JP Morgan downgraded Clovis Oncology, Inc. Longwood Capital Partners Llc sold 20,361 shares as Clovis Oncology Inc (CLVS)'s stock declined 20.61%. Insiders have sold 9,000 shares of company stock valued at $653,220 in the last 90 days. Clovis Oncology Inc now has $2.89 billion valuation. About 6.15 million shares traded. (NASDAQ:CLVS). Artal Group invested 0.04% of its portfolio in Clovis Oncology, Inc. It has outperformed by 266.01% the S&P500.
Analysts await Clovis Oncology, Inc. (NASDAQ:CLVS) or 3,725 shares. They expect $1.66 earnings per share, down 1.78% or $0.03 from last year's $1.69 per share. After $-1.24 actual EPS reported by Clovis Oncology, Inc. for the previous quarter, Wall Street now forecasts 2.42% negative EPS growth.
Since June 15, 2017, it had 0 buys, and 1 sale for $185,460 activity. Morgan Stanley initiated Clovis Oncology, Inc. Molina Healthcare Inc (NYSE:MOH) was raised too. CACI International Inc (CACI) has risen 32.11% since December 7, 2016 and is uptrending. Therefore 70% are positive. BidaskClub lowered Clovis Oncology from a "strong-buy" rating to a "buy" rating in a report on Wednesday, August 9th. The rating was upgraded by PiperJaffray to "Overweight" on Thursday, January 26. (NASDAQ:CLVS) on Monday, April 4 with "Neutral" rating. The firm has "Buy" rating given on Tuesday, June 20 by Janney Capital. Norges Bank bought a new position in shares of Clovis Oncology during the fourth quarter worth $13,155,000. The company was maintained on Wednesday, September 21 by Stifel Nicolaus.
A supplemental new drug application (sNDA) for Rubraca (rucaparib), a poly (ADP-ribose) polymerase (PARP) inhibitor, to be used as a maintenance treatment for patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy, has been granted a priority review by the Food and Drug Administration (FDA), according to manufacturer Clovis Oncology. (NASDAQ:CLVS) has "Hold" rating given on Monday, July 31 by Oppenheimer. Leerink Swann restated a "buy" rating and issued a $107.00 price target on shares of Clovis Oncology in a report on Monday, September 18th. On Friday, September 23 the stock rating was maintained by SunTrust with "Buy".
Esperion Therapeutics, Inc. analysts gave 6 buy-equivalent recommendations, 0 sells and 2 holds. Cubist Systematic Strategies Limited Com reported 0% stake. (NASDAQ:TXMD). 1492 Cap Lc stated it has 0.97% of its portfolio in TherapeuticsMD, Inc. (NASDAQ:CLVS) for 29,900 shares. Candriam Luxembourg S.C.A. now owns 217,500 shares of the biopharmaceutical company's stock valued at $17,922,000 after purchasing an additional 48,500 shares during the period.
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally.
Longwood Capital Partners Llc decreased Clovis Oncology Inc (CLVS) stake by 50.45% reported in 2017Q2 SEC filing. (NASDAQ:CLVS) for 212 shares. Acadian Asset Mngmt Lc has invested 0% in Clovis Oncology, Inc. (NASDAQ:CONE). Aperio Limited Liability Company holds 0.02% or 59,271 shares. California-based Franklin Resource Inc has invested 0.03% in TherapeuticsMD, Inc. (NASDAQ:CLVS) for 1.08 million shares. Tiaa Cref Limited Liability Corporation invested 0.02% of its portfolio in Clovis Oncology, Inc. 10,000 were reported by Moore Mgmt Lp. Moreover, Legal And General Public Limited has 0% invested in Clovis Oncology, Inc.
The stock increased 0.54% or $0.7 during the last trading session, reaching $131.05. About 1.17 million shares traded. FCB Financial Holdings, Inc. Vermilion Energy Inc. (NYSE:VET) has risen 5.95% since December 7, 2016 and is uptrending. It has outperformed by 13.93% the S&P500.
Investors sentiment increased to 1.6 in 2017 Q2. The biopharmaceutical company reported ($1.24) EPS for the quarter, missing analysts' consensus estimates of ($1.18) by ($0.06). 47 funds opened positions while 113 raised stakes. It also reduced Masco Corp (NYSE:MAS) stake by 28,503 shares and now owns 62,684 shares. Raymond James Associates reported 0% of its portfolio in TherapeuticsMD, Inc. Moreover, Hudock Gp Limited Com has 0% invested in CyrusOne Inc. Quantbot Technologies Lp accumulated 385 shares. Zevenbergen Capital Investments Llc has 0.03% invested in CyrusOne Inc.
Citadel Ltd Liability accumulated 821,817 shares.
- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.